Regeneron's Trading Volume Drops 54.65% to $380 Million, Ranks 202nd in Market

On June 30, 2025, Regeneron's trading volume was $380 million, a significant decrease of 54.65% from the previous day, ranking 202nd in the day's stock market. Regeneron Pharmaceuticals (REGN) rose 0.77%, marking three consecutive days of gains, with a total increase of 0.91% over the past three days.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on July 15, 2025, to stockholders of record at the close of business on June 28, 2025. This dividend reflects the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) has reported positive results from its Phase 3 clinical trial of REGN-EYE01, an investigational treatment for age-related macular degeneration (AMD). The trial met its primary endpoint, demonstrating a statistically significant improvement in visual acuity compared to the control group. These results support the potential of REGN-EYE01 as a new treatment option for patients with AMD.

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize innovative therapies for rare diseases. The collaboration will leverage Regeneron's expertise in protein engineering and the partner's strengths in gene therapy to address unmet medical needs in rare disease areas. This partnership is expected to accelerate the development of new treatments and expand Regeneron's pipeline.